OncoMethylome Announces Positive Research Results on its Urine Test for Prostate Cancer
Approximately 15% of prostate cancers occur in men who are commonly not examined for prostate cancer because their PSA levels fall within the normal range of 0- 4.0ng/mL. Published studies indicate that 10% of men with a low PSA level (2.5-4.0 ng/mL) have prostate cancer. Veridex is developing a urine test, which was licensed from OncoMethylome in December 2006, to help identify men in this group who are likely to have prostate cancer.
Veridex examined urine from 255 men enrolled in a multi-center clinical trial, of which 52 had a PSA in the range of 2.5 - 4ng/mL, which, under current screening guidelines, is still considered within the normal range. In this challenging patient group, the prototype test demonstrated a sensitivity of 58% and a specificity of 88% in urine samples. This data demonstrates that the test has the potential to detect cancers missed by the current screening process. Based on these findings, Veridex is planning to carry out prospective clinical validation trials.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.